The short version of triple agonist fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-09-10. Anything still debated is marked as such rather than presented as settled.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
| Property | Value | Notes |
|---|---|---|
| Compound class | Synthetic triple-agonist peptide | Single linear chain carrying three receptor activities |
| Reported molecular weight | Approximately 4731 Da | Calculated from the published sequence; sources vary slightly |
| Appearance | White to off-white lyophilized powder | Typical of purified research-grade peptides |
| Solubility | Freely soluble in water; poorly soluble in nonpolar solvents | Dissolves in aqueous buffer near neutral pH |
| Storage of dry powder | -20 °C or below, desiccated, protected from light | Avoid repeated temperature cycling |
Solid peptide is generally held as a lyophilised powder at low temperature to slow degradation, with desiccant to limit moisture uptake. Reconstituted solutions are less stable and are usually kept refrigerated and protected from light for short periods. Repeated freeze-thaw cycles are avoided because they encourage aggregation. Laboratory handling includes work in a fume hood or laminar flow cabinet to limit inhalation and contamination. Weighing and transfer steps are performed with antistatic tools to reduce static-driven loss of fine powder.
Characterising a peptide of this size relies on a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact molecule from related impurities, while electrospray mass spectrometry confirms molecular mass and detects truncation or oxidation products. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates modified residues. Because the molecule carries a lipid chain, assays must also distinguish the correctly conjugated product from incompletely acylated species.
Peptides in this class degrade mainly through hydrolysis, oxidation, and aggregation. The lipid modification improves plasma residence time but can also promote self-association in aqueous solution at higher concentrations. Oxidation of methionine and deamidation of asparagine residues are common chemical liabilities that accumulate during storage. Stability studies therefore track purity loss, aggregate formation, and changes in receptor-binding potency over time under defined temperature and humidity conditions.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
== Physiological functions == The sites of APLNR receptor expression are linked to the different functions played by Elabela in the organism. Despite that, Elabela is capable of signaling independently of APLNR in human embryonic stem cells and certain cancer cell lines including OVISE.
Last but not least, specific cleavage of poly (ADP-ribose) polymerase (PARP) and a decrease in pro-caspase9 and 3 were also induced by arenobufagin treatment. PARP is mainly involved in cell repair and programmed cell death. After treatment with arenobufagin, some cells make more autophagosomes and lysosomes, whereas other cells undergo apoptosis. Arenobufagin also leads to increased expression of LC3-II, Biclin1(initial vesicle formation), Atg5 (elongation and completion), Atg9, Atg16L1 and p62/SQSTM1, all proteins which induce autophagy. Blockers of autophagy increase the cytotoxic effect of arenobufagin. Addition of 3-MA increases the proportion of cells in which there in enlarged PARP cleavage and limited caspase-9 and caspase-3 cleavage. This indicates that autophagy pathways protect the cell against apoptosis by arenobufagin. It was hypothesized that arenobufagin may inhibit the PI3K/Akt pathway in controlling cell death and differentiation in response to external stimuli. It was found that arenobufagin inhibited the proteins Akt, PDK1 and PI3K, whereas it stimulated the PHEN-protein. It does this by altering the degree of phosphorylation. All these proteins are involved in the PI3/Akt pathway. Further down the pathway, arenobufagin indirectly inhibits the mTOR-protein, which is involved in apoptosis as well as in autophagy. The biotransformation of arenobufagin by Alternaria alternata leads to the following three metabolites: 3-oxo-arenobufagin (1a), ψ-bufarenogin (1b), and 3- oxo- ψ-bufarenogin (1c).
=== Former faculty === Persons who had left the faculty through death, retirement, termination, or by accepting an offer somewhere else. Former members of the faculty are listed by divisions. Alumnus degrees are depicted in italic type.
=== Forensics === BRT's Forensics division offers services in serology screening, DNA profiling, and case review. These services are contracted by government agencies, defense counsel, and private citizens or organizations for several applications. Government agencies contract BRT’s Forensic division for criminal and “no-suspect” casework. The Laboratory offers STR analysis and Y-STR analysis with each of the commercial kits commonly used in the US. The Forensic division is accredited by ASCLD/Lab – International and meets the requirements of ISO/IEC 17025. BRT has also received accreditation from the Texas Department of Public Safety and has been approved by the Maryland State Police Forensic Science Division for analysis of casework that can be uploaded to CODIS. The Laboratory adheres to current Scientific Working Group on DNA Analysis Methods (SWGDAM) and FBI DNA Advisory Board (DAB) guidelines. Defense counsel contract BRT Laboratories to perform case reviews, which may include assistance with the interpretation of subpoena documents, sample retesting, and/or expert witness testimony. The Forensic division also provides serology and DNA profiling services to private citizens for infidelity testing and to private organizations or medical professionals for sample identity verification.
Sources: en.wikipedia.org
Conrad Elvehjem, the son of Norwegian emigrants to Wisconsin, was born in McFarland, Wisconsin. He progressed through the secondary schools and the University of Wisconsin, where he received his PhD in 1927 with mentor E.B. Hart for his studies of the importance of copper in iron-deficiency anemia. A National Research Council fellowship permitted a year at Cambridge University in England. Elvehjem began teaching in agricultural chemistry at the University of Wisconsin in 1923, and became a full professor in 1936. He became chairman of the biochemistry department in 1944 and dean of the graduate school in 1946, at 45 years of age. He served as dean of the graduate school until he became the university's 13th president in 1958. Picking up on the work of Joseph Goldberger, he found that nicotinic acid cured black tongue in dogs, an analogous disease to pellagra. In the previous year, Elvehjem and his colleague Carl J. Koehn had found that a filtrate factor from a liver extract could cure diet-induced pellagra in chicks. That filtrate extract was designated as the vitamin G fraction, after the late Goldberger. To confirm their findings in dogs, they induced black tongue in these animals with the Goldberger diet of yellow corn, before supplementing the diet with the vitamin G fraction. Elvehjem and his colleagues later were able to isolate and identify nicotinamide and nicotinic acid from vitamin G as the curative factors for black tongue in dogs.
Sulfite reductase (NADPH) (EC 1.8.1.2, sulfite (reduced nicotinamide adenine dinucleotide phosphate) reductase, NADPH-sulfite reductase, NADPH-dependent sulfite reductase, H2S-NADP oxidoreductase, sulfite reductase (NADPH2)) is an enzyme with systematic name hydrogen-sulfide:NADP+ oxidoreductase. This enzyme catalises the following chemical reaction:
== Career == Bigbie attended Ball State University. In 1998, he played collegiate summer baseball with the Wareham Gatemen of the Cape Cod Baseball League. Bigbie was drafted by the Baltimore Orioles in the 1st round (21st pick overall) of the 1999 Major League Baseball amateur draft and played over four years (2001–2005) for the Orioles before being traded during the 2005 season to the Colorado Rockies. Bigbie played the remainder of 2005 season for the Rockies. On December 8, 2005, the Rockies traded him and Aaron Miles to the St. Louis Cardinals for pitcher Ray King. On February 2, 2007, he signed a minor league deal with the Los Angeles Dodgers. Bigbie exercised a free agent option in his contract on June 1, 2007, and on June 11 signed a minor league contract with the Braves. During his six-year career, he posted a .268 batting average, hitting 31 home runs and amassing 322 hits in 375 games. Bigbie is an average fielder, but has an above-average arm. He batted .240 in 2006 with the Cardinals, also posting only 1 RBI, in 17 games. In December 2007, it was announced that he had agreed to a deal to play for the Yokohama Bay Stars of the Nippon Professional Baseball (NPB). Bigbie made a comeback for the 2010 season, playing for the Edmonton Capitals of the Golden Baseball League. Bigbie was named the DH for Baseball America's 2010 All-Independent Leagues Team.
He is the author of the 2010 book Stable Isotope Forensics, the first textbook dedicated to principles and forensic applications of stable isotope analytical techniques, which since has been extensively up-dated. The second edition, Stable Isotope Forensics - Methods and Forensic Applications of Stable Isotope Analysis, was published in 2018. On 26 December 2022 Meier-Augenstein appeared in the 2022 Royal Institution Christmas Lectures, with the title 'Secrets of Forensic Science', delivered by Sue Black, Baroness Black of Strome.
"Standard weapon grade plutonium requires a 240Pu content of no more than 6.5%." which is 65,000 ppm, and the analogous 238Pu was produced in levels of 0.5% (5,000 ppm) or less). Gun-type fission weapons additionally need low levels (1 ppm range) of light impurities, to keep the neutron generation low. The production of "clean" 233U, low in 232U, requires a few factors: 1) obtaining a relatively pure 232Th source, low in 230Th (which also transmutes to 232U), 2) moderating the incident neutrons to have an energy not higher that 6 MeV (too-high energy neutrons cause the 232Th (n,2n) → 231Th reaction) and 3) removing the thorium sample from neutron flux before the 233U concentration builds up to a too high level, in order to avoid fissioning the 233U itself (which would produce energetic neutrons). The Molten-Salt Reactor Experiment (MSRE) used 233U that contained 222 ppm 232U.
Sources: en.wikipedia.org
=== Injectable amylin analogues === Amylin agonist analogues slow gastric emptying and suppress glucagon. They have all the incretins actions except stimulation of insulin secretion. As of 2007, pramlintide is the only clinically available amylin analogue. Like insulin, it is administered by subcutaneous injection. The most frequent and severe adverse effect of pramlintide is nausea, which occurs mostly at the beginning of treatment and gradually reduces. Typical reductions in A1C values are 0.5–1.0%.
== History == The consumption of wheatgrass in the Western world began in the 1930s as a result of experiments conducted by Charles Schnabel in his attempts to popularize the plant. By 1940, cans of Schnabel's powdered grass were on sale in major drug stores throughout the United States and Canada. Ann Wigmore was also a strong advocate for the consumption of wheatgrass as a part of a raw food diet. Wigmore, founder of the Hippocrates Health Institute, believed that wheatgrass, as a part of a raw food diet, would cleanse the body of toxins while providing a proper balance of nutrients as a whole food. She also taught that wheatgrass could be used to treat those with serious disease. Both of these claims are believed by many reputable health institutes to be entirely unfounded by facts, and possibly dangerous.
{\displaystyle {\begin{aligned}{\bar {I}}_{1}&=J^{-2/3}~I_{1}~;~~I_{1}=\lambda _{1}^{2}+\lambda _{2}^{2}+\lambda _{3}^{2}~;~~J=\det({\boldsymbol {F}})\\{\bar {I}}_{2}&=J^{-4/3}~I_{2}~;~~I_{2}=\lambda _{1}^{2}\lambda _{2}^{2}+\lambda _{2}^{2}\lambda _{3}^{2}+\lambda _{3}^{2}\lambda _{1}^{2}\end{aligned}}}
=== Antimicrobial === Sweat may serve an antimicrobial function, like that of earwax or other secretory fluids (e.g., tears, saliva, and milk). It does this through a combination of glycoproteins that either bind directly to, or prevent the binding of microbes to, the skin and seem to form part of the innate immune system. In 2001, researchers at Eberhard-Karls University in Tübingen, Germany, isolated a large protein called dermcidin from skin. This protein, which could be cleaved into other antimicrobial peptides, was shown to be effective at killing some species of bacteria and fungi that affect humans, including Escherichia coli, Enterococcus faecalis, Staphylococcus aureus, and Candida albicans. It was active at high salt concentrations and in the acidity range of human sweat, where it was present at concentrations of 1–10 mg/ml.
Sources: en.wikipedia.org
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.
No. As of the most recent public information it remains investigational in every jurisdiction. Material sold under this name outside trials is a research chemical, not an approved medicine. Current status should always be checked against regulator notices.
Dual agonists act on two receptors, usually GIP and GLP-1. Retatrutide adds glucagon receptor activity, which is associated with increased energy expenditure. Whether that third component adds clinically meaningful benefit over dual agonism remains an open question.
It is a synthetic peptide triagonist that engages GIP, GLP-1, and glucagon receptors. Investigational compounds in this class are studied for metabolic conditions rather than for a single organ system.